# Wittgenbio

> Publicly sourced profile assembled by Optimly, in the Optimly AI Brand Index. Last refreshed 2026-10-04.

- **Business Profile:** https://optimly.ai/brand/wittgenbio
- **Dataset:** https://optimly.ai/brand/wittgenbio.json
- **Markdown:** https://optimly.ai/brand/wittgenbio/llms.txt
- **Official website:** https://wittgenbio.com
- **Slug:** wittgenbio
- **Categories:** biotechnology, diagnostics-labs, healthcare-it

## Overview

- **Tagline:** Unrivaled precision using Single-cell GenAI to extract cellular-level biomarkers from archived bulk RNA or pathological image data, offering 7x higher precision in identifying responders, 95% cost savings over traditional single-cell profiling, and regulator-ready patient stratification at trial scale without the single-cell burden.
Source: Brand's website (https://wittgenbio.com) · 2026-10-04

- **Description:** Wittgenbio provides a Single-Cell GenAI powered Virtual Cell-to-Patient profiling technology to accelerate clinical success. Their platform transforms bulk RNA or pathological image data into regulator-ready patient stratification insights, de-risking clinical trials and enabling marker-driven therapeutic discovery.
Source: Brand's website (https://wittgenbio.com) · 2026-10-04

## Offerings

- **Core capabilities:**
  - Virtual Cell-to-Patient profiling technology
  - LEIBER-X platform. These solutions provide single-cell clarity from bulk or image samples for patient stratification
  - biomarker discovery
  - and clinical trial de-risking.
Source: Brand's website (https://wittgenbio.com) · 2026-10-04

- **Pricing:** Not explicitly mentioned, but implies a service or platform subscription model based on the value proposition of cost savings and accelerated research.
Source: Brand's website (https://wittgenbio.com) · 2026-10-04

## Audience

- **Target industry:** Clinical leaders, pharmaceutical companies, and academic partners involved in therapeutic development and patient stratification.
Source: Brand's website (https://wittgenbio.com) · 2026-10-04

Page last updated 2026-10-04.